SCM
KYNB

Stevens Capital Management’s Kyntra Bio KYNB Stock Holding History

Stevens Capital Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-894
Closed -$1.06M – 812
2017
Q4 		$1.06M Buy
894
+84
+10% +$105K 0.04% 417
2017
Q3 		$1.09M Buy
+810
New +$854K 0.04% 414
2016
Q3 		– Sell
-506
Closed -$208K – 969
2016
Q2 		$208K Buy
+506
New +$232K 0.01% 773

Other funds holding KYNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Stevens Capital Management's KYNB Position: Q1 2018 in Review

Stevens Capital Management sold out of Kyntra Bio (KYNB) in Q1 2018, closing a stake of 894 shares — an estimated $1.06M sold.

Stevens Capital Management first reported a position in KYNB in Q2 2016 and held it in 3 quarters. The position peaked at $1.09M in Q3 2017. 193 funds tracked by Wall St. Rank hold KYNB as of Q1 2018.

  • Stevens Capital Management reported no remaining Kyntra Bio position as of Q1 2018 after selling out during the quarter.
  • Stevens Capital Management sold 894 Kyntra Bio shares in Q1 2018, an estimated $1.06M.
  • Stevens Capital Management first reported a position in Kyntra Bio in Q2 2016 and held it in 3 quarters.
  • Stevens Capital Management's Kyntra Bio position peaked at $1.09M in Q3 2017.
  • 193 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2018.

Based on Stevens Capital Management's 13F filing for Q1 2018, filed 8 May 2018.